Irvine, CA (PRWEB) April 07, 2014 <\/p>\n
Proove Biosciences, the leader in Personalized Pain Medicine testing services, exhibited and presented research from three studies at the American Society of Interventional Pain Physicians' (ASIPP) 16th annual meeting in New Orleans. The event took place at the Hilton New Orleans Riverside hotel, this weekend, April 4-6. <\/p>\n
Proove submitted abstracts on three IRB-approved clinical studies to ASIPP for presentation at the annual meeting. Out of many abstracts submitted by various researchers, ASIPP only accepted 20 studies for presentation and publication. All three Proove study abstracts were accepted for poster presentation, and one of Proove's study abstracts was selected in the \"Top 5 Posters\" presented before the general session on Saturday afternoon. <\/p>\n
Specifically, the company plans to present: Predictive Risk of Injury Complications Enduring Over one Year Using Genetic Predisposition (P.R.I.C.E.) Study, MED Scale to Predict Hydrocodone Efficacy versus the Pain VAS Score Study, and Perception of Analgesia in Narcotic Users with Chronic Pain: A Multi-Center Cross-Sectional Study Comparing Genotype to Pain VAS (P.A.I.N.) Study. <\/p>\n
On Saturday afternoon, Proove's Medical Director for Pain and Addiction, Daniel Schwarz, MD, MROC presented information on Prooves P.R.I.C.E. study during the \"Top 5 Posters\" session. <\/p>\n
The PRICE Study demonstrates how a proprietary algorithm can identify workers' compensation claims that are at risk for extending beyond one-year. In this study of 272 patients, a PRICE score of 3 was able to predict claims extending beyond 1 year with an accuracy of 52% positive predictive value (+PPV) and a sensitivity of 88% and specificity of 92%. <\/p>\n
The MED Scale to Predict Hydrocodone Efficacy versus the Pain VAS Score Study validates the Proove proprietary MED Scale to identify therapeutic outcomes in pain medicine. This abstract demonstrates how the MED Scale used with chronic non-cancer pain patients taking hydrocodone correlates with the commonly used Pain Visual Analog Scale (VAS). Proove research exhibited findings on how the MED Scale may be a reliable assessment of therapeutic efficacy for chronic pain patients treated with hydrocodone. <\/p>\n
The purpose of the PAIN Study is to evaluate whether genotype, or SNP variations can help objectively stratify patient perception of pain among chronic pain patients taking narcotics. Statistical data supports Prooves findings that a proprietary genotypic analysis from Proove can stratify pain perception, and may be a more objective method to define subjective numerical rating scales based on patient perceptions. <\/p>\n
ASIPP was created to support the needs of physicians who practice interventional pain management. The society offers extensive opportunities to train and educate physicians on the latest science behind interventional pain management, and is one of the most I involved and influential medical political action groups. <\/p>\n
Proove Biosciences is excited to be participating in ASIPPs Annual Meeting, and to share and present our clinical data on how our Proove Genetic tests have been helping to improve clinical outcomes in pain medicine and reducing costs within our healthcare system, stated Brian Meshkin, President of Proove Biosciences and author of the three studies. \"Collaborating with our Medical Advisory Board members who are leaders in ASIPP like Dr. Andrea Trescot and Dr. Sandy Silverman, we are very pleased to continue leading the industry in pain medicine genetics testing and research.\" <\/p>\n
<\/p>\n
See the rest here:<\/p>\n
Proove Biosciences Research Recognized and Presented at the American Society of Interventional Pain Physicians 16th ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Irvine, CA (PRWEB) April 07, 2014 Proove Biosciences, the leader in Personalized Pain Medicine testing services, exhibited and presented research from three studies at the American Society of Interventional Pain Physicians' (ASIPP) 16th annual meeting in New Orleans. Continue reading